Arena Pharmaceuticals Inc $4.23

down 0.00


20/8/2014 04:00 PM  |  NASDAQ : ARNA  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get ARNA Trend Analysis - it has underperformed the S&P 500 by 59%

Partner Headlines

  1. Earnings Scheduled For August 1, 2014

    Benzinga
  2. Benzinga's Top #PreMarket Losers

    Benzinga
  3. Markets Marginally Lower Ahead Of Earnings Season

    Benzinga
  4. Arena Pharmaceutical Shares Dive On News CEO Sold 40% Of His Shares

    Benzinga
  5. Benzinga's Top #PreMarket Losers

    Benzinga
  6. Events Scheduled for Week of Jun. 16th to Jun. 20th

    Benzinga
  7. FDA delays Orexigen drug

    IBD
  8. Is Arena Pharmaceuticals A Biotech Stock To Watch?

    Benzinga
  9. Orexigen Obesity Drug Decision Delayed By FDA

    IBD
  10. Orexigen Shares Plummet Following FDA Decision; Competition Gets A Bump

    Benzinga
  11. Arena Pharma Posts Q1 Loss Of $0.12/Share, Misses By ~$0.02/Share

    Benzinga
  12. Earnings Scheduled For May 12, 2014

    Benzinga
  13. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE Moving ...

    Benzinga
  14. Benzinga's Top #PreMarket Losers

    Benzinga
  15. Earnings Scheduled For February 27, 2014

    Benzinga
  16. Bad Earnings Weigh In On Diet Stocks

    Benzinga
  17. Top Trending Tickers On StockTwits For February 14

    Benzinga
  18. #PreMarket Primer: Friday, February 14: A Turnaround

    Benzinga
  19. Arena Pharmaceuticals Announces Filing for Marketing Authorization of BELVIQ® ...

    Benzinga
  20. Celgene To Release Earnings At J.P. Morgan Event Mon.

    IBD
  21. The Top Five Drug Launches Of 2013

    IBD
  22. (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance on Financial ...

    GuruFocus
  23. Benzinga's Top #PreMarket Gainers

    Benzinga
  24. Market Wrap For November 11: Relative Quiet as Traders and Investors Observe ...

    Benzinga
  25. Market Wrap For November 8: Markets Erase Thursday's Losses; Dow Companies ...

    Benzinga
  26. Arena Pharmaceuticals, Eisai Expand Marketing and Supply Agreement for ...

    Benzinga
  27. Nasdaq Leads Stocks Lower; Twitter IPO Opens To 80% Gain

    IBD
  28. How Arena’s “$3 Billion” Belviq Withered

    YCharts
  29. Benzinga's Top #PreMarket Losers

    Benzinga
  30. Market Wrap For Tuesday, October 15: Earnings Reports And White House Progress ...

    Benzinga
  31. Mid-Afternoon Market Update: Tumi Holdings Rises Amid Market Decline

    Benzinga
  32. Mid-Morning Market Update: Markets Slip; Citigroup Profit Misses Estimates

    Benzinga
  33. UPDATE: Arena Says Eisai Will Double BELVIQ Sales Force to 400 Reps

    Benzinga
  34. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and Raises PT

    Benzinga
  35. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD
  36. Benzinga's Top Pre-Market Losers

    Benzinga
  37. Market Wrap For September 30: Debt Ceiling And Government Shutdown Loom

    Benzinga
  38. Mid-Afternoon Market Update: Mellanox Rallies As Market Remains in the ...

    Benzinga
  39. Mid-Day Market Update: Dow Falls Over 100 Points; Active Network Shares ...

    Benzinga
  40. Mid-Morning Market Update: Markets Open Lower; Cal-Maine Q1 Net Profit ...

    Benzinga
  41. UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following Management ...

    Benzinga
  42. Arena Pharma Offers Update on Eisai Launch of BELVIQ, Says Placing Ads ...

    Benzinga
  43. Stocks Hitting 52-Week Lows

    Benzinga
  44. BMO Considers Recent Sales Data on Arena's Belviq, Maintains Market Perform ...

    Benzinga
  45. CEO Shift Aside, Whose Weight-Loss Pill’s Ahead

    YCharts
  46. Stocks Hitting 52-Week Lows

    Benzinga
  47. Stocks Hitting 52-Week Lows

    Benzinga
  48. Arena Pharma Reports Closing of Phase 1b Clinical Trial for APD811

    Benzinga
  49. Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)

    Benzinga
  50. It's Hard to Sell a Pill That Nobody's Heard Of

    YCharts
Trading Center